BioStone Animal Health Received a Grant Fund from National Pork Board for Classical Swine Fever (CSF) Diagnostic Research

DALLAS-FORT WORTH, TX — February 12, 2021 — We are pleased to announce that BioStone Animal Health was awarded a grant from The National Pork Board titled “An Enzyme-Linked Immunoassay (ELISA) to detect Classical Swine Fever antibodies and to Differentiate Infected from Vaccinated Animals (DIVA)”. In collaboration with Kansas State University, we will work on the development of a diagnostic test to Differentiate Infected from Vaccinated Animals (DIVA). Our collaborators will provide critical support to validate the DIVA ELISA with experimentally infected animals at Kansas State University in a BSL III laboratory. The DIVA ELISA will be based on the detection of two target antibodies against the E2 antigen and against the Erns antigen. The DIVA test will be a companion diagnostic for CSF subunit vaccines based on the E2 antigen. Through the development of the CSF DIVA, we aim to produce new diagnostic tools.

About BioStone Animal Health — BioStone Animal Health is a Dallas, TX-based biotechnology company that provides innovative solutions for animal health. BioStone Animal Health works together with our worldwide partners to offer a portfolio of animal disease diagnostic products as well as test kits and reagents for vaccine testing that enables performing a rapid evaluation of the efficacies, stability, consistency, and potency of common animal vaccines. By making these test kits available to the international community, BioStone strives to actively promote and participate in global animal health initiatives. For more information about BioStone Animal Health, visit